Danish laboratory Novo Nordisk has announced the launch of its anti-obesity drug Wegovy in France, but the country's drug safety agency has already said it will monitor its use to ensure it is not misused for aesthetic purposes.
Wegovy is one of the GLP-1 analogues (aGLP-1), a new type of treatment that has become very popular in the fight against obesity as it helps patients lose weight quickly.
Due to the injection of an active substance, semaglutide, the same as that used in Novo Nordisk's other anti-diabetic drug Ozempic, patients feel full.
If used in higher doses and in cases where the patient is obese, the substance can lead to vomiting, nausea or diarrhoea. (...)
Sem comentários:
Enviar um comentário